BioCentury
ARTICLE | Financial News

Cancer play X4 raises $37.5M

September 2, 2015 1:38 AM UTC

X4 Pharmaceuticals Inc. (Cambridge, Mass.) raised $37.5 million in an equity funding round, according to an SEC filing. The company is developing oral CXC chemokine receptor type 4 ( CXCR4; NPY3R) antagonists to treat refractory solid tumors.

X4 founder Renato Skerlj was among the discoverers and developers of Mozobil plerixafor, a CXCR4 antagonist marketed to mobilize hematopoietic stem cells in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). Sanofi (Euronext:SAN; NYSE:SNY) gained Mozobil through its 2011 acquisition of Genzyme Corp. ...